BRAF and melanoma: Despite the conspicuous clinical response of BRAF-mutated melanoma to BRAF inhibitors and the dramatic response rate of immune checkpoint therapies, the prognosis of melanoma patients remains unfavorable, mainly due to the development of drug resistance.